Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?

finance.yahoo.com · 2026-08-14

On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme’s proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. […]

TickrTrends take: Halozyme Therapeutics operates in the Healthcare sector where revenue scale alone does not determine economic efficiency or profitability potential. TickrTrends' Undervalued designation suggests the market may not be fully pricing in HALO's ability to generate returns on its asset base relative to its current valuation. Investors focused on valuation should monitor whether HALO can demonstrate superior unit economics and margin expansion compared to larger competitors like Incyte, as these operational metrics would support the undervaluation thesis.

Read the full story at finance.yahoo.com →